Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibody Structure01:10

Antibody Structure

60.5K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.5K
Viral Structure00:56

Viral Structure

62.8K
Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
62.8K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

801
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
801

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magnetoencephalography Reveals Neuroprotection of COVID-19 Vaccination in Nonhuman Primates.

Vaccines·2026
Same author

Ultra-short recombinant Art v 1 immunotherapy induces rapid immune modulation in mugwort allergy: A Phase I trial.

Allergology international : official journal of the Japanese Society of Allergology·2026
Same author

Bilateral Peripheral Facial Nerve Palsy: A Rare Clinical Picture.

European journal of case reports in internal medicine·2026
Same author

Adjuvant Strategies to Improve the Efficacy of Allergen Immunotherapy.

Journal of inflammation research·2026
Same author

Design and Synthesis of New Pyrazolo[1,5-c]quinazolin-5-amines as Potential TLR7/8 Modulators.

ChemMedChem·2026
Same author

Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease.

Nature medicine·2026

Related Experiment Video

Updated: Jul 28, 2025

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.1K

In Silico Structure-Based Vaccine Design.

Sakshi Piplani1, David Winkler2,3,4, Yoshikazu Honda-Okubo1

  • 1Vaxine Pty Ltd, Adelaide, SA, Australia.

Methods in Molecular Biology (Clifton, N.J.)
|May 31, 2023
PubMed
Summary

Structure-based vaccine design (SBVD) advances computational vaccine development by using protein structures to create new vaccine candidates. This method, highlighted by COVID-19 vaccine design, offers new targets and opportunities for future vaccine discovery.

Keywords:
COVID-19Computer-aided vaccine designDe novo designFocused library designHigh-throughput virtual screeningMolecular dockingProtein modelingSARS-CoV-2Structure-based vaccine designTarget selection

More Related Videos

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

154
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.0K

Related Experiment Videos

Last Updated: Jul 28, 2025

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.1K
Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

154
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.0K

Area of Science:

  • Computational biology
  • Vaccinology
  • Structural biology

Background:

  • Structure-based vaccine design (SBVD) leverages detailed protein structural information for novel vaccine candidate development.
  • Advances in modeling protein and antibody structures unlock new vaccine targets and discovery avenues.
  • The SARS-CoV-2 spike protein serves as a key example for SBVD strategies.

Approach:

  • Comprehensive overview of the current state of in silico SBVD.
  • Discussion of existing challenges and limitations in computational vaccine design.
  • Case study illustrating SBVD strategies in the design of COVID-19 vaccines.

Key Points:

  • SBVD utilizes structural data to engineer precise vaccine components.
  • Rapid advancements in structural modeling accelerate the identification of potential vaccine targets.
  • The COVID-19 pandemic highlighted the efficacy and potential of SBVD.

Conclusions:

  • In silico SBVD is a powerful computational approach for vaccine development.
  • Overcoming current challenges will further enhance the capabilities of SBVD.
  • SBVD holds significant promise for future vaccine discovery across various diseases.